Weight-loss drugmaker Novo Nordisk’s shares fall on disappointing study
Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday after it announced disappointing results of a new drug study. The drugmaker said clinical trials had demonstrated that overweight subjects using the weight-loss drug Cagrisema had lost an average of 22.
Denmark’s Novo Nordisk and the US’s Eli Lilly on 32.5 and 57.6 times 2024 earnings respectively — are predicated on the fact that their heft will allow them to keep on top of the competition. Novo ...
STOCKHOLM (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense ...
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Copenhagen, Denmark Friday, December 20, 2024, 10:00 Hrs [IST] ...
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...
FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little/File Photo · Reuters / Reuters ...
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback